Table 1. Demographics and clinical characteristics of non-diabetic and T2D subjects enrolled in the study, expressed as mean ± SD for continuous variables and number of subjects for categorical variables.
| All Subjects Enrolled | Subset | |||
|---|---|---|---|---|
|
Non-
Diabetic (n = 33) |
Type 2
Diabetic (n = 20) |
Non-
Diabetic (n = 19) |
Type 2
Diabetic (n = 12) |
|
| Sex | ||||
| Male | 19 (58%) | 11 (55%) | 12 (63%) | 7 (58%) |
| Female | 14 (42%) | 9 (45%) | 7 (37%) | 5 (42%) |
| Race | ||||
| White / Caucasian | 27 (82%) | 16 (80%) | 16 (84%) | 9 (75%) |
| Black / African-American | 5 (15%) | 4 (20%) | 2 (11%) | 3 (25%) |
| Asian | 1 (3%) | 0 | 1 (5%) | 0 |
| Basic Clinical Characteristics | ||||
| Age (yrs) | 64.3 ± 10.9 | 65.9 ± 10.0 | 61.6 ± 11.6 | 63.8 ± 9.7 |
| Height (m) | 1.70 ± 0.11 | 1.68 ± 0.08 | 1.72 ± 0.09 | 1.69 ± 0.08 |
| Weight (kg) | 86.2 ± 23.2 | 94.0 ± 15.2 | 85.2 ± 25.1 | 94.0 ± 16.0 |
| BMI (kg/m2) | 30.0 ± 8.0 | 33.5 ± 5.5φ | 28.7 ± 7.8 | 33.0 ± 5.1φ |
| Diabetic Status | ||||
| HbA1c (at PAT, %) | 5.70 ± 0.24 | 6.99 ± 1.34** | 5.64 ± 0.21 | 7.45 ± 1.51* |
| Diabetes Medication Used | ||||
| Metformin | - | 11 (55%) | 7 (58%) | |
| Insulin | - | 2 (10%) | 4 (33%) | |
| Other# | - | 7 (35%) | 1 (9%) | |
*
p≤0.05
**
p≤0.0001
φ
0.05<p≤0.10
#
Other group represents (a) any subject who took a T2D medication that is not metformin or insulin, and (b) any subject who took multiple T2D medications simultaneously, including insulin, sulfonylureas, GLP-1 receptor agonists, biguanides, dopamine receptor agonists, and SGLT2 inhibitors.